Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775252 | 1.00 | HRH3 (0.62) | HRH3MAOBHRH2HRH1MAOA | |
| SCHEMBL1178972 | 0.96 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL85615 | 0.96 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL1179056 | 0.96 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL1776447 | 0.92 | HRH3 (0.71) | HRH3MAOBHRH2HRH1MAOA | |
| SCHEMBL1776848 | 0.92 | HRH3 (0.57) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL1178719 | 0.92 | HRH3 (0.57) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL6727200 | 0.87 | HRH3 (0.63) | HRH3MAOBHRH2HRH1MAOA | |
| SCHEMBL4467743 | 0.82 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL4562819 | 0.82 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221298-B1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2221298-B1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8193176-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193176-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193176-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8183387-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183387-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065667-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065667-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-7888354-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888354-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888354-B2 | Phenylpyrazole derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2221298-A1 | PHENYLPYRAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065668-A1 | PHENYLPYRAZOLE DERIVATIVES | PER2, CRY1, HCRTR1 | HRH3 5/4885MAOB 482/4885HRH2 42/4885 |
| US-20110065667-A1 | PHENYLPYRAZOLE DERIVATIVES | PER2, CRY1, HCRTR1 | HRH3 5/4885MAOB 482/4885HRH2 42/4885 |
| US-20100267687-A1 | PHENYLPYRAZOLE DERIVATIVES | PER2, CRY1, HCRTR1 | HRH3 5/4885MAOB 482/4885HRH2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.